GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuBase Therapeutics Inc (STU:O7P) » Definitions » Shiller PE Ratio

NeuBase Therapeutics (STU:O7P) Shiller PE Ratio : (As of Jun. 10, 2024)


View and export this data going back to 2019. Start your Free Trial

What is NeuBase Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


NeuBase Therapeutics Shiller PE Ratio Historical Data

The historical data trend for NeuBase Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuBase Therapeutics Shiller PE Ratio Chart

NeuBase Therapeutics Annual Data
Trend Sep12 Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

NeuBase Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NeuBase Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, NeuBase Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeuBase Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NeuBase Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where NeuBase Therapeutics's Shiller PE Ratio falls into.



NeuBase Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

NeuBase Therapeutics's E10 for the quarter that ended in Sep. 2023 is calculated as:

For example, NeuBase Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-0.618/129.8595*129.8595
=-0.618

Current CPI (Sep. 2023) = 129.8595.

NeuBase Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201312 -0.073 98.326 -0.096
201403 -0.072 99.695 -0.094
201406 -0.066 100.560 -0.085
201409 -0.101 100.428 -0.131
201412 -0.146 99.070 -0.191
201503 -0.111 99.621 -0.145
201506 -0.098 100.684 -0.126
201509 -0.116 100.392 -0.150
201512 -0.184 99.792 -0.239
201603 -0.153 100.470 -0.198
201606 -0.214 101.688 -0.273
201609 -0.187 101.861 -0.238
201612 -0.199 101.863 -0.254
201703 -0.196 102.862 -0.247
201706 -0.062 103.349 -0.078
201709 -0.067 104.136 -0.084
201712 -0.063 104.011 -0.079
201803 -0.624 105.290 -0.770
201806 -0.163 106.317 -0.199
201809 -38.504 106.507 -46.946
201812 -0.014 105.998 -0.017
201903 -0.354 107.251 -0.429
201906 -0.354 108.070 -0.425
201909 -24.413 108.329 -29.265
201912 -0.234 108.420 -0.280
202003 -0.235 108.902 -0.280
202006 -0.160 108.767 -0.191
202009 -0.170 109.815 -0.201
202012 -0.148 109.897 -0.175
202103 -0.202 111.754 -0.235
202106 -0.241 114.631 -0.273
202109 -0.179 115.734 -0.201
202112 -0.212 117.630 -0.234
202203 -0.272 121.301 -0.291
202206 -0.246 125.017 -0.256
202209 -0.242 125.227 -0.251
202212 -0.123 125.222 -0.128
202303 -0.112 127.348 -0.114
202306 -1.883 128.729 -1.900
202309 -0.618 129.860 -0.618

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


NeuBase Therapeutics  (STU:O7P) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


NeuBase Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of NeuBase Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


NeuBase Therapeutics (STU:O7P) Business Description

Traded in Other Exchanges
Address
350 Technology Drive, Suite 421, Pittsburgh, PA, USA, 15219
NeuBase Therapeutics Inc is a pre-clinical stage biopharmaceutical company. It is engaged in the development of gene silencing therapies with its synthetic antisense oligonucleotides. Its Patrol platform is focused on the development of drugs for rare genetic diseases such as Huntington's Disease, Myotonic Dystrophy and Familial Parkinson's Disease among others.

NeuBase Therapeutics (STU:O7P) Headlines

No Headlines